Non-Hodgkin s lymphomas (NHLs) are a
|
|
- Aubrey Moody
- 8 years ago
- Views:
Transcription
1 Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in the elderly is sometimes planned with curative intent, more often the aim is to prolong life with minimal symptoms from disease or therapies. Dr Clare Rowntree discusses the two most common forms of NHL seen in this group and reviews management options. DR CLARE ROWNTREE is a consultant haematologist at the University Hospital of Wales Non-Hodgkin s lymphomas (NHLs) are a heterogenous group of tumours of the lymphoid system. The majority (90 per cent) of NHLs arise from B-cells and the remaining 10 per cent arise from T-cells. The incidence of NHL is increasing in both Europe and the US at 5 10 per cent per year, with the current incidence being cases per 100, The reasons for this increase are unclear at the present time. The incidence in the elderly is increasing even more rapidly which, taken with an ageing population, has significant implications for future planning of haemato-oncology services. Clinical presentations of lymphoma vary due to the multisystem nature of the disease. Lymphadenopathy is a common presenting feature but the disease can present in many guises from solid tumours in sites such as the orbit, to skin lesions, to non-specific symptoms of fever and weight loss. To make a diagnosis of lymphoma, a biopsy of involved tissue is always required. Classification of the type of lymphoma, according to the Revised European-American Classification of Lymphoid Neoplasms (REAL) 2, can be difficult and review by a specialist haemato-pathologist is usually required. Once a diagnosis of lymphoma has been made it is important to make an assessment of the aggressiveness of the lymphoma, the extent of disease, and the patient s prognosis september 2006 / midlife and beyond / geriatric medicine
2 34 Oncology and possibilities of cure. A management plan can then be formulated within the setting of a lymphoma multidisciplinary team (MDT), which will have a core membership of radiation oncologists, haemato-oncologists, pathologists, radiologists, palliative care specialists and clinical nurse specialists. In the elderly, treatment may be planned with curative intent, but more frequently the aim will be to achieve a prolonged life expectancy with minimal symptoms from disease or therapies. Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL) is classed as a CD20 (surface marker found on B-cells) positive aggressive lymphoma. It is the most commonly diagnosed lymphoma, accounting for 40 per cent of new cases. Of these new cases, more than 50 per cent occur in patients over 60 years of age making the elderly the largest group of patients with this disease 3. DLBCL is classified as an aggressive lymphoma because survival is limited due to disease in the absence of effective therapy. At presentation, approximately 75 per cent of all patients with DLBCL will have widespread disease and this percentage is higher in the elderly. In order to try to predict prognosis at diagnosis, the International Prognostic Index (IPI) was published in Five independent variables were identified as being important negative predictors for survival: > age over 60 years; > performance status (Eastern Cooperative Oncology Group scale) 3 ; > a raised lactate dehydrogenase level; > involvement of two or more extranodal sites; > stage of disease. A higher score predicts an increased risk of death due to lower remission rates and increased relapse rates. The IPI illustrates why the elderly diagnosed with DLBCL have had a poorer outlook than their younger counterparts. For many years the gold standard chemotherapy regimen used to treat DLBCL has been cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) given every 21 days. Historically, six to eight cycles of CHOP resulted in cure in approximately 40 per cent of patients, although figures were lower in the elderly. Clinicians often have concerns about delivering CHOP-like regimens to them as it is well documented that when treated with chemotherapy for lymphoma they appear to be more susceptible to neutropenic sepsis, particularly during early cycles of treatment 4. Not only are neutropenic infectious complications more common in the elderly, they are also more severe. Patients over 65 are hospitalised more frequently for febrile neutropenia following CHOP, require longer stays in hospital and have increased mortality 5. In the past this has often lead to clinicians reducing doses of chemotherapy or changing to non-anthracycline containing regimens. It has been suggested that downgrading treatment is the main reason for the traditionally inferior outcomes seen within this age group 6. Over recent years, two important studies have had a major impact on treatment of DLBCL in the elderly. The first was from Groupe d Etude des Lymphomes de l Adulte (GELA) 7, where patients between the ages of 60 and 80 years with advanced DLBCL were randomised to receive CHOP or CHOP plus rituximab a chimeric (humanmouse) anti-cd20 monoclonal antibody. The addition of rituximab to CHOP chemotherapy resulted in significantly superior disease-free and overall survival. The two-year disease-free survival rose from 40 per cent to 58 per cent with no significant increases in toxicity. The survival benefit was seen in all patient groups and was not dependent on the presenting IPI score. The German non-hodgkin s study group also looked at patients over 60 years with DLBCL 8. They showed that increasing the intensity of CHOP to a 14-day schedule also significantly improved survival. However, the toxicity of this approach in the elderly was increased. From these data, it has become clear that many elderly patients should be treated in the same way as younger patients ie, with curative intent. Rituximab-CHOP has now become the gold standard first-line therapy for DLBCL in all patients up to 80 years within the UK. Patients over 80, or those with a poor biological age (their physical age as opposed to their actual age), should be considered as having incurable disease for the most part and the emphasis should be placed on life prolonging treatment with minimal toxicity 9. Conventional therapy may not be feasible or appropriate in this age group, and time must be taken with the patient to discuss their options fully. Rituximabbased regimens, such as rituximab with cyclophosphamide, vincristine and prednisolone geriatric medicine / midlife and beyond / september 2006
3 36 Oncology (CVP), are usually considered for this age group although single agent chemotherapy for symptom control may be more appropriate. Shared care between hospital teams, general practitioners and community palliative care teams can be very beneficial in this often frail group of patients. DLBCL in relapse Relapse of DLBCL in the elderly is typically widespread and often associated with a poor performance status. The only curative option for relapsed DLBCL at the current time is aggressive salvage chemotherapy consolidated with high dose therapy (HDT) and autologous stem cell transplantation. The only data from randomised trials verifying this approach are in young patients 10. However, in the minority of elderly patients who otherwise have a good performance status and chemosensitive disease, HDT should be considered as an option. For all other elderly patients, the possibility of cure with second-line therapies is very low 11. In this group a palliative approach may be offered, at which time quality of life and patient choice should be of prime concern. Further chemotherapy, either single agent or combination, is frequently used. The aim of this is a second remission or, more simply, symptom control. Radiolabelled anti-cd20 antibodies have been shown to induce responses in 44 per cent of patients with DLBCL at relapse and can be given with minimal side effects 12. However, at the current time, these are not routinely available in the UK outside of a clinical trial. Follicular lymphoma Follicular lymphoma (FL) is also a CD20 positive B-cell lymphoma, and it is the second most frequent type of NHL in the UK. The prognosis of patients with FL is broadly linked to the extent of the disease. Unfortunately, the majority of patients will have widespread disease at diagnosis. However, per cent of patients will have truly localised disease at presentation and the treatment of choice is radiotherapy. This will give long-term diseasefree survival in approximately 45 per cent of patients 13. The remaining patients have essentially incurable disease. Despite various advances in treatment of FL over the past decade, the prognosis remains largely
4 Oncology 37 compromise and do not have a high tumour burden. The pros and cons of a watch and wait policy must be carefully explained to the patient. Even with adequate support, some patients find this approach unacceptable and will opt for early treatment. First-line therapy for FL Rituximab has also been extensively investigated in patients with FL and has shown to be highly effective. As a single agent it is very well tolerated and induces responses in 67 per cent of de novo patients 18. Consequently the British National Lymphoma Investigation group are currently running a trial comparing watch and wait with single agent rituximab at diagnosis. The results of such trials are eagerly awaited. unchanged with the average life expectancy being 8 10 years 14. The course of FL is characterised by initial responses to treatment followed by relapse. FL is classed as an indolent lymphoma, but approximately one-third will transform to a high grade lymphoma and this event is usually associated with a very poor outcome. Age over 60 years is again a predictor of decreased survival in FL 15. There are no specific FL trials in the elderly and a broad range of therapeutic options are available, ranging from a watch and wait approach to a reduced intensity allogeneic stem cell transplant. These options are outlined below. Watch and wait It is well documented that as many as 25 per cent of tumours in patients with untreated FL will undergo spontaneous regression 16. With a watch and wait policy, the median time until chemotherapy is required is three years. No overall differences in survival have been observed when treatment is delayed compared with patients treated with conventional chemotherapy at the outset. For patients over 70 years, the chances of either requiring chemotherapy or dying of FL at 10 years are 40 per cent 17. Consequently, it has long been acceptable to adopt a watch and wait policy for patients who do not have systemic symptoms from their disease or signs of major organ Many trials have compared combination chemotherapy with or without rituximab in firstline therapy for advanced stage FL. Most have shown a significant increase in response rates and progression-free survival with the addition of rituximab. Whether these improved outcomes will translate into prolonged survival is not yet clear. The improvements in responses occur in both chemotherapy naive and previously treated patients. Based on these data, many haematooncologists will now use CVP in combination with rituximab as first-line therapy in the UK 19. Relapse of FL When FL relapses, the median survival for a patient is four and a half years. There are some emerging data suggesting that HDT with autologous stem cell rescue or an allogeneic stem cell transplant with reduced intensity conditioning may offer the possibility of long-term disease freesurvival in patients with relapsed disease 20. While these procedures are too toxic for many elderly patients, they may be appropriate for occasional patients who lack other poor risk features and have a good performance status. For all other patients, the emphasis should be on attaining a sustained second response with minimal toxicity. These patients should all be discussed and treated within a lymphoma MDT setting. Options include a further period of watch and wait, secondline chemotherapy regimens or monoclonal antibody therapies. Results with radiolabelled monoclonal anti-cd20 antibodies are very encouraging in this group of patients, with per september 2006 / midlife and beyond / geriatric medicine
5 38 Oncology Key points > The incidence of lymphoma is increasing within the elderly population. > With more intensive therapies, the survival rates in elderly patients with NHL are approaching those in younger patients. > The recent addition of novel antibody therapies to conventional chemotherapy has made dramatic improvements to survival in elderly patients with DLBCL. > All patients with lymphoma should be cared for within the lymphoma MDT setting. cent of relapsed patients showing a good response 21. Once an elderly patient with FL has relapsed for the second time, it may be appropriate to adopt a purely palliative approach. The importance of community team involvement in the patient s care by this stage of their illness cannot be overemphasised as these patients are often reluctant to spend much of their time in the hospital environment. Conclusion Over the past few years there has been a significant change in emphasis in the management of NHL within the elderly. All the evidence now suggests older patients with DLBCL should be considered for treatment with curative intent. For the first time, results from phase III trials show similar overall response rates and overall survival figures in both young and elderly patients diagnosed with aggressive lymphoma. The challenge facing us all will be to provide adequate support to older patients undergoing increasingly toxic regimens. Faced with an ageing population and an increasing incidence of lymphoma, we will need to organise our resources so we are able to offer curative treatment to those where we can. However, cure is still not an option for the majority of elderly patients with lymphoma. For these remaining patients we must strive to provide high quality, multidisciplinary based care, that achieves a good quality of life with minimal side effects from our therapies. Conflict of interest: none declared. References 1. Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-hodgkin s lymphoma in Europe. Ann Oncol 1997; 8: Harris NL, Jaffe ES, Stein H, et al. A revised European-American classifi cation of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: The International Non-Hodgkin s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin s lymphoma. N Engl J Med 1993; 329: Wasil T and Litchtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly (review). The Oncologist 2005; 10: Balducci L and Repetto L. Increased risk of myelotoxicity in elderly patients with non- Hodgkin lymphoma. Cancer 2004; 100: Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic signifi cance of actual dose intensity in diffuse large-cell lymphoma: results of a treestructured survival analysis. J Clin Oncol 1990; 8: Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3- weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: Coiffer B. State-of-the-Art Therapeutics: Diffuse B-cell lymphoma. J Clin Oncol 2005; 23: Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin s lymphoma. N Engl J Med 1995; 333: Jabbour E, Chalhoub B, Suzan F, et al. Outcome of elderly patients with aggressive Non-Hodgkin s lymphoma refractory to or relapsing after fi rst-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004; 45(7): Morschhauser F, Huglo D, Martinelli R, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed / refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial (abstract). Blood 2004; 104: 41a 13. Peterson PM, Gospodarowitz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved fi eld radiotherapy alone. Proc ASCO. 2004; 23: Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumourburden follicular lymphomas between an initial no-treatment policy, predmustine, or interferon alfa. A randomised study from the Groupe d Etude des Lymphomes Folliculaires. J Clin Oncol. 1997; 15: Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma Prognostic Index. Blood 2004; 104: Horning SJ and Rosenberg SA. The natural history of initially untreated low-grade non- Hodgkin s Lymphoma. N Engl J Med 1984; 311: Ardeshna K, Smith P, Norton A, et al. Long term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced stage non-hodgkin s lymphoma: a randomised controlled trial. Lancet 2003; 362: Ghielmini M, Shmitz SF, Cogliatti SB, et al. Prolonged treatment with Rituximab in patients with follicular lymphoma signifi cantly increases event-free survival and response duration compared with the standard x 4 weekly schedule. Blood 2004; 103: Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as fi rst line treatment for advanced follicular lymphoma. Blood 2005; 105: Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: Current status and future perspectives (review). J Clin Onc 2005; 23: Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I Tositumomab for relapsed or refractory B-cell non-hodgkin lymphoma. Updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: geriatric medicine / midlife and beyond / september 2006
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationRituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008
Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationRituximab in the Management of Follicular Lymphoma
Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationollicular Lymphoma The following investigations are indicated for most patients with follicular lymphoma:
ollicular Lymphoma Drs. Kevin Imrie & Matthew Cheung Updated August 2007* Fximab Updates: Ritu maintenance therapy Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma
More informationSummary. 516 THE LANCET Vol 362 August 16, 2003 www.thelancet.com For personal use. Only reproduce with permission from The Lancet
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-hodgkin lymphoma: a randomised controlled trial K M Ardeshna, P Smith, A Norton, B W
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationState-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr INTRODUCTION
State-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationEffective on or after May 1, 2015,, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies
Effective on or after May 1, 2015,, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies Name of Policy: Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
More informationRituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationSalvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma
IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationHow do I find the best place to get treatment for my lymphoma?
Produced November 2010 Next revision due November 2012 How do I find the best place to get treatment for my lymphoma? Introduction Fortunately this is not a question that patients with cancers of the blood
More informationDIFFUSE LARGE B-CELL LYMPHOMA
DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype
More informationLymphoma: The Roleof Nurses in the Treatment Process
Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationRadioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma. Original Policy Date
MP 8.01.28 Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationDiffuse large B-cell lymphoma: the curable disease?
Hematology Meeting Reports 2007; 1(5):77 86 Diffuse large B-cell lymphoma: the curable disease? Michael Pfreundschuh Med Klinik I, Saarland University Medical School, Homburg/Saar, Germany Corresponding
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationFollicular Lymphoma. 1. Introduction. 2. Diagnosis. 3. Baseline Investigations
Follicular Lymphoma Follicular Lymphoma Treatment policy prepared by Dr. Louise Bordeleau 1. Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma. These lymphomas
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationFollicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationIn the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
More informationThe use of monoclonal antibodies in the setting of HSCT
The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin
More informationFOLLICULAR LYMPHOMA. Executive Summary
FOLLICULAR LYMPHOMA Executive Summary Follicular lymphoma (FL) is the most common indolent lymphoma and the second most common non-hodgkin lymphoma accounting for about 10-20% of all lymphomas in Western
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationrituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited
rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationChemoimmunotherapy resistant follicular lymphoma A single institutional study
Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More information-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities
More informationDE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1
Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive
More informationJ Clin Oncol 22:4302-4311. 2004 by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 21 NOVEMBER 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin s Lymphoma: A Nationwide
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationMedical Policy Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
Medical Policy Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationLymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
More informationRituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationMonoclonal Antibody Therapy for Lymphoma: Targeting CD20
Monoclonal Antibody Therapy for Lymphoma: Targeting CD20 Session Chair: Jonathan W. Freidberg, MD Speakers: Michele Ghielmini, MD; Jonathan W. Friedberg, MD; and John P. Leonard, MD Multimodality Therapies
More informationPhase II Trial of R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients
Original Article Phase II Trial R -C H O P V s C H O P C hem otherapy in Pakistani D iffuse Large B cell Lym phom a Patients Objective: To determine response and relapse rates in diffuse large B cell lymphoma
More informationHealthPACT Health Policy Advisory Committee on Technology Australia and New Zealand Technology Brief
HealthPACT Health Policy Advisory Committee on Technology Australia and New Zealand Technology Brief 90Y Zevalin for the treatment of non-hodgkin s lymphoma (v1.0) August 2011 State of Queensland (Queensland
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationRituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma
DOI: 10.3310/hta13suppl2/06 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma A Boland, A Bagust,
More informationFollicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center
Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More information馬 偕 紀 念 醫 院 新 竹 分 院 淋 巴 癌 放 射 治 療 指 引
馬 偕 紀 念 醫 院 新 竹 分 院 淋 巴 癌 放 射 治 療 指 引 2010.05.12 新 增 2013.06.03 四 版 前 言 新 竹 馬 偕 醫 院 放 射 腫 瘤 科 藉 由 跨 院 聯 合 會 議 機 制 進 行 討 論, 以 制 定 符 合 現 狀 之 淋 巴 癌 放 射 治 療 指 引 本 院 淋 巴 癌 放 射 治 療 指 引 的 建 立, 係 參 考 國 內 外 文 獻
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationLymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
More informationFollicular Lymphoma: Current Management and Future Directions
Treatment decisions and outcomes for patients with follicular lymphoma may be improved with newer diagnostic tests and novel targeted agents. George Van Hook. Barns in Summer. Oil on linen, 22 28. Follicular
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationPerspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationAggressive non-hodgkin s lymphoma long-term survival for all patients?
Hematology Meeting Reports 2007; 1(4):27 41 Aggressive non-hodgkin s lymphoma long-term survival for all patients? Bertrand Coiffier 1 Jacques Tabacof 2 Zhi-Xiang Shen 3 Ulrich Jäger 4 1 Hospices Civils
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More information